Recent Blog Posts

View Post: New analysis shows SYMBICORT® improved airflow obstruction in ...
9 Nov 2009
For patients with COPD, the approved dosage of SYMBICORT is 160/4.5 mcg, two inhalations twice daily. Lower respiratory tract infections, including pneumonia, have been reported following the inhaled administration of ... Celli, B., Tashkin , D., Rennard, S., McElhattan, E., Martin, U. Bronchodilator Reversibility and Onset with Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) in Patients with Chronic Obstructive Pulmonary Disease (COPD) [poster]. ...
View Blog: AZ US news feed - http://www.astrazeneca-us.com/

---

View Post: Regional Respiratory Medicine: Symbicort catching up with Seretide ...
22 Nov 2009 by RRM Web log  
Secondly, for Astra-Zeneca and Symbicort (budesonide/eformoterol) it's all about catching up with Glaxo and Seretide (fluticasone/salmeterol). And they just might do it yet. The study was a randomised, placebo controlled trial of Spiriva ... The benefits of this combination of inhaled medications in COPD now seems beyond dispute. There seems to be a class effect (ie Symbicort and Seretide are each beneficial) and we can expect Symbicort to get PBS listing in Australia at ...
View Blog: Regional Respiratory Medicine - http://regionalmedicine.blogspot.com/

---

View Post: NPCi Blog: Addition of inhaled budesonide/formoterol to tiotropium ...
5 Nov 2009
This NPCi blog discusses the findings of a short-term RCT that claims benefits for the addition of inhaled budesonide/formoterol to tiotropium (i.e. triple vs. single therapy) in patients with COPD. The 12-week, study involved 660 ...
View Blog: NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/

---

View Post: Triple versus single therapy in COPD « NPCi blog
4 Nov 2009 by bowersc  
A short-term randomised controlled trial claims benefits for the addition of inhaled budesonide/formoterol to tiotropium (i.e. triple vs. single therapy) in patients with COPD. However, limitations of the study question its validity and ...
View Blog: NPCi blog - http://www.npci.org.uk/blog/

---

View Post: Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest ...
17 Nov 2009 by Education For Health  
Budesonide/Formoterol Plus Tiotropium Improves the Quality of Life of Patients With Severe COPD. May 20th, 2009 LUTON, England - News Release for the Medical Media Preliminary results from a double-blind, randomised, ... To view the Multimedia News Release, please click: www.prnewswire.com/mnr/astrazeneca/38533/ The study known as CLIMB, compared 12 weeks treatment with budesonide/formoterol (400/12 mcg one inhalation twice-daily) plus tiotropium (18 micro g one ...
View Blog: PR Hub - http://blog.taragana.com/pr/

---

View Post: MedWire News - Respiratory - Budesonide not linked to pneumonia ...
12 Nov 2009
MedWire News Treatment with budesonide is not associated with an increased risk for pneumonia in patients with chronic obstructive pulmonary disease or asthma, research shows. MedWire News. ... “In COPD, some clinical trials have reported an increased incidence of pneumonia for patients receiving inhaled corticosteroids (ICS),” explained lead researcher Don Sin (University of British Columbia, Vancouver, Canada) at Chest 2009 in San Diego, California USA. ...
View Blog: MedWire News - Respiratory - http://www.medwire-news.md/48/Respiratory.html

---

View Post: Phase 2b study of oglemilast for treatment of Chronic Obstructive ...
19 Aug 2009
Forest Laboratories and Glenmark Pharmaceuticals announced top-line results from a Phase 2b dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). ... The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and manufactured by Dey L.P., a subsidiary of Mylan, because the medications might ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: Triple therapy halves exacerbations in moderate-to-severe COPD ...
8 Oct 2009 by admin  
Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting â-agonist (LABA), an inhaled corticosteroid (ICS) and an anti-muscarinic agent, according to ... Journal of Respiratory and Critical Care Medicine, researchers found that adding budesonide, an ICS, and formoterol, a LABA, to the anti-muscarinic agent, tiotropium, reduced the rate of severe exacerbations in COPD patients by 62 percent. ...
View Blog: BreakThrough Digest Medical News - http://www.breakthroughdigest.com/

---

View Post: Respiratory Research
Full text
The bioavailability and airway ... ...
View Blog: The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial

---

View Post: Argenta Discovery Publishes Positive Data From a Phase II Proof of ...
15 Sep 2009
Argenta Discovery Publishes Positive Data From a Phase II Proof of Concept Trial with Co-Administration of Inhaled ADC4022 Plus Budesonide Study in COPD. Harlow, UK, 15 Sept 2009 - Argenta Discovery Limited, the respiratory drug ...
View Blog: Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html

---